Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

University of Michigan Spinoff ONL Therapeutics Receives Federal Designation for Retinal Drug

Tuesday, April 5, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

ONL Therapeutics Inc., an Ann Arbor-based spinoff from the University of Michigan, has received a crucial orphan-drug designation from the U.S. Food and Drug Administration for its lead compound, which has the working name of ONL1204.

The drug, expected to go into human trials this year, is used to limit the damage caused to patients who suffer retinal detachments.

 Read more.


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal